MedCap

518.00 SEK

-3.00 %

Less than 1K followers

MCAP

NASDAQ Stockholm

Investment

Financials

Overview

Financials & Estimates

Ownership

Investor consensus

-3.00 %

-5.13 %

-16.18 %

+17.46 %

-13.81 %

-12.50 %

+147.85 %

+133.33 %

+5,028.71 %

MedCap operates in the investment industry and focuses on long-term equity investments in medical technology and pharmaceutical companies. The company's portfolio includes companies in sectors such as biotechnology and medical technology. The operations are primarily concentrated in Sweden, with a primary presence in the Stockholm region. MedCap was founded in 2001 and is headquartered in Stockholm.

Market cap

7.79B SEK

Turnover

9.71M SEK

Revenue

1.81B

EBIT %

15.07 %

P/E

37

Dividend yield-%

-

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

6.2

2026

Annual report '25

29.4

2026

Interim report Q1'26

21.7

2026

Interim report Q2'26

All

Press releases

3rd party

ShowingAll content types

Press release10/27/2025, 1:26 PM

Redeye: MedCap (Q3 review) - Healthy Q3 figures

Regulatory press release10/24/2025, 4:30 AM

MedCap AB: Strong organic and acquired growth; EBITA increased by 32%

Regulatory press release10/1/2025, 1:00 PM

MedCap AB: Abilia acquires LivAssured

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release7/23/2025, 12:05 PM

Redeye: MedCap Q2 2025 - The rise, fall, and rise again

Regulatory press release7/23/2025, 4:30 AM

MedCap AB: Strong quarter with 20 percent EBITA growth and acquisition in Specialty Pharma

Regulatory press release7/21/2025, 10:00 AM

MedCap AB: MedCap's Business Area Specialty Pharma Completes the Acquisition of XGX Pharma

Regulatory press release6/25/2025, 5:30 AM

MedCap AB: MedCap's Business Area Specialty Pharma Acquires XGX Pharma

Press release4/30/2025, 5:47 AM

Redeye: MedCap Q1 2025 - Step by step

Regulatory press release4/29/2025, 4:30 AM

MedCap AB: 7% growth and EBITA margin recovers to 17%

Press release2/3/2025, 7:53 AM

Redeye: MedCap Q4 2024 - A tale of euphoria and despair

Regulatory press release1/31/2025, 5:30 AM

MedCap AB: Good demand but unsatisfactory earnings. Strong cash flow.

Regulatory press release1/31/2025, 5:30 AM

MedCap AB: MedCap's Business Area Assistive Tech Acquires Danrehab

Regulatory press release1/16/2025, 5:30 PM

MedCap AB: Preliminary result for the fourth quarter

Press release11/4/2024, 9:24 AM

Redeye: Redeye Initiates Coverage of MedCap

Regulatory press release10/25/2024, 4:30 AM

MedCap AB: Profit growth, stronger cash flow and acquisitions

Regulatory press release7/24/2024, 4:30 AM

MedCap AB: Continued strong growth - adjusted EBITA increased by 13 percent

Regulatory press release7/24/2024, 4:30 AM

MedCap AB: Abilia acquires Picomed and Alert-IT

Press release7/12/2024, 8:00 AM

MedCap AB: Changed date for the release of MedCap's half-year report 2024

Regulatory press release5/3/2024, 4:30 AM

MedCap AB: Strong first quarter - EBITA up 46 percent

Press release3/25/2024, 2:45 PM

MedCap AB: Abilia acquires Kompany AS and the product Komp

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.